Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.35 |
| ▸ | NR2C2 | P49116 | 2/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.35 |
| ▸ | RELA | Q04206 | 2/20 | 0.35 |
| ▸ | TAB1 | Q15750 | 2/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 4/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7020659 | 0.94 | MKNK1 (0.35) | MKNK1MKNK2NFKB1NR2C2NFKB2 | |
| SCHEMBL7017717 | 0.78 | MAP3K14 (0.38) | MKNK1MKNK2MAP3K14LCKCDK2 | |
| SCHEMBL7016351 | 0.76 | MKNK1 (0.55) | MKNK1MKNK2LCK | |
| SCHEMBL7018022 | 0.75 | LCK (0.43) | MKNK1MKNK2MAP3K14LCKCDK2 | |
| SCHEMBL7018015 | 0.75 | LCK (0.43) | MKNK1MKNK2MAP3K14LCKCDK2 | |
| SCHEMBL7014852 | 0.74 | LCK (0.64) | MKNK1MKNK2LCK | |
| SCHEMBL7592438 | 0.74 | LCK (0.64) | MKNK1MKNK2LCK | |
| SCHEMBL7020602 | 0.73 | MKNK1 (0.38) | MKNK1MKNK2LCKCDK2 | |
| SCHEMBL7020656 | 0.69 | MKNK1 (0.55) | MKNK1MKNK2LCK | |
| SCHEMBL7020406 | 0.68 | LCK (0.64) | MKNK1MKNK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1206265-B1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-6498165-B1 | PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS | MERCK & CO., INC. | 2002-12-24 | — | — | US | disclosed |